Sino Biopharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Sino Biopharmaceutical's earnings have been declining at an average annual rate of -13.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 2.9% per year. Sino Biopharmaceutical's return on equity is 12%, and it has net margins of 7.7%.
Anahtar bilgiler
-13.6%
Kazanç büyüme oranı
-13.4%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 5.6% |
Gelir büyüme oranı | 2.9% |
Özkaynak getirisi | 12.0% |
Net Marj | 7.7% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Oct 02Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Gelir ve Gider Dağılımı
Sino Biopharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 27,790 | 2,142 | 11,689 | 0 |
31 Mar 24 | 26,995 | 1,995 | 11,378 | 0 |
31 Dec 23 | 26,199 | 1,847 | 11,067 | 0 |
30 Jun 23 | 25,116 | 1,254 | 11,001 | 0 |
31 Mar 23 | 25,571 | 1,656 | 11,355 | 0 |
31 Dec 22 | 26,026 | 2,059 | 11,709 | 0 |
30 Sep 22 | 28,241 | 5,296 | 12,705 | 0 |
30 Jun 22 | 27,701 | 8,049 | 12,846 | 0 |
31 Mar 22 | 27,215 | 13,655 | 12,669 | 0 |
31 Dec 21 | 26,861 | 14,608 | 12,704 | 0 |
30 Sep 21 | 26,129 | 12,465 | 12,718 | 0 |
30 Jun 21 | 25,353 | 10,011 | 12,754 | 0 |
31 Mar 21 | 24,668 | 3,809 | 12,198 | 0 |
31 Dec 20 | 23,647 | 2,771 | 11,629 | 0 |
30 Sep 20 | 23,039 | 2,302 | 11,254 | 0 |
30 Jun 20 | 24,354 | 2,558 | 11,490 | 0 |
31 Mar 20 | 24,248 | 2,781 | 11,762 | 0 |
31 Dec 19 | 24,234 | 2,762 | 11,797 | 0 |
30 Sep 19 | 24,479 | 9,101 | 12,544 | 0 |
30 Jun 19 | 23,691 | 9,125 | 11,801 | 0 |
31 Mar 19 | 22,444 | 9,132 | 11,036 | 0 |
31 Dec 18 | 20,889 | 9,046 | 10,268 | 0 |
30 Sep 18 | 19,103 | 2,567 | 8,799 | 0 |
30 Jun 18 | 17,062 | 2,436 | 7,921 | 0 |
31 Mar 18 | 15,609 | 2,363 | 7,334 | 0 |
31 Dec 17 | 14,819 | 2,171 | 6,905 | 0 |
30 Sep 17 | 14,491 | 2,115 | 6,680 | 0 |
30 Jun 17 | 14,258 | 1,862 | 6,668 | 0 |
31 Mar 17 | 13,899 | 1,789 | 6,525 | 0 |
31 Dec 16 | 13,543 | 1,637 | 6,493 | 0 |
30 Sep 16 | 13,271 | 1,674 | 6,344 | 0 |
30 Jun 16 | 12,858 | 1,604 | 6,272 | 0 |
31 Mar 16 | 12,507 | 1,575 | 6,084 | 0 |
31 Dec 15 | 12,189 | 1,490 | 5,974 | 0 |
30 Sep 15 | 12,030 | 1,432 | 5,994 | 0 |
30 Jun 15 | 11,124 | 1,447 | 5,483 | 0 |
31 Mar 15 | 10,552 | 1,263 | 5,252 | 0 |
31 Dec 14 | 9,900 | 1,210 | 4,933 | 0 |
30 Sep 14 | 9,205 | 1,074 | 4,457 | 0 |
30 Jun 14 | 8,876 | 951 | 4,366 | 0 |
31 Mar 14 | 8,434 | 886 | 4,287 | 0 |
31 Dec 13 | 7,731 | 809 | 3,945 | 0 |
Kaliteli Kazançlar: 1177 has high quality earnings.
Büyüyen Kar Marjı: 1177's current net profit margins (7.7%) are higher than last year (5%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 1177's earnings have declined by 13.6% per year over the past 5 years.
Büyüme Hızlandırma: 1177's earnings growth over the past year (70.9%) exceeds its 5-year average (-13.6% per year).
Kazançlar vs. Sektör: 1177 earnings growth over the past year (70.9%) exceeded the Pharmaceuticals industry 6.4%.
Özkaynak Getirisi
Yüksek ROE: 1177's Return on Equity (12%) is considered low.